Form 4: LifeMD's Chief Innovation Officer Reports Acquisition of 30,000 Shares

Stefan Galluppi, Chief Innovation Officer of LifeMD, Inc., reports acquiring 30,000 shares of common stock on March 31, 2025, due to the vesting of performance stock.

Summary

• Stefan Galluppi, the Chief Innovation Officer of LifeMD, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on March 31, 2025, where Galluppi acquired 30,000 shares of LifeMD common stock.
• This acquisition was due to the vesting of performance stock.
• The price per share was $0.
• Following the transaction, Galluppi directly owns 165,449 shares of LifeMD common stock.
• Galluppi also indirectly owns 1,644,800 shares through American Nutra Tech, LLC, which he wholly owns.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock vesting, which is neither particularly positive nor negative.

Positives

• The vesting of performance stock suggests that the company or the individual achieved certain performance targets.

Industry Context

Form 4 filings are a routine part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it reflects an increase in insider ownership.

Key Dates

Keywords

LifeMD, Galluppi, insider trading, Form 4, beneficial ownership, performance stock, LFMD, Chief Innovation Officer